nodes	percent_of_prediction	percent_of_DWPC	metapath
Paricalcitol—CYP3A4—Everolimus—kidney cancer	0.105	0.293	CbGbCtD
Paricalcitol—CYP3A4—Temsirolimus—kidney cancer	0.0712	0.198	CbGbCtD
Paricalcitol—CYP3A4—Pazopanib—kidney cancer	0.0374	0.104	CbGbCtD
Paricalcitol—CYP3A4—Erlotinib—kidney cancer	0.0267	0.0741	CbGbCtD
Paricalcitol—CYP3A4—Paclitaxel—kidney cancer	0.0244	0.0678	CbGbCtD
Paricalcitol—CYP3A4—Sorafenib—kidney cancer	0.0217	0.0603	CbGbCtD
Paricalcitol—CYP3A4—Vinblastine—kidney cancer	0.0214	0.0595	CbGbCtD
Paricalcitol—CYP3A4—Vincristine—kidney cancer	0.0211	0.0585	CbGbCtD
Paricalcitol—CYP3A4—Sunitinib—kidney cancer	0.0176	0.0488	CbGbCtD
Paricalcitol—CYP3A4—Doxorubicin—kidney cancer	0.0132	0.0366	CbGbCtD
Paricalcitol—CYP24A1—nephron tubule—kidney cancer	0.00856	0.118	CbGeAlD
Paricalcitol—UGT1A4—renal system—kidney cancer	0.00779	0.108	CbGeAlD
Paricalcitol—CYP24A1—renal system—kidney cancer	0.00779	0.108	CbGeAlD
Paricalcitol—CYP24A1—kidney—kidney cancer	0.00753	0.104	CbGeAlD
Paricalcitol—UGT1A4—kidney—kidney cancer	0.00753	0.104	CbGeAlD
Paricalcitol—VDR—Ovarian Infertility Genes—SYNE2—kidney cancer	0.00736	0.0647	CbGpPWpGaD
Paricalcitol—CYP24A1—cortex of kidney—kidney cancer	0.00733	0.101	CbGeAlD
Paricalcitol—UGT1A4—Porphyrin metabolism—ALAD—kidney cancer	0.00669	0.0588	CbGpPWpGaD
Paricalcitol—CYP3A4—urine—kidney cancer	0.00586	0.0809	CbGeAlD
Paricalcitol—VDR—nephron tubule—kidney cancer	0.00472	0.0652	CbGeAlD
Paricalcitol—VDR—renal system—kidney cancer	0.00429	0.0592	CbGeAlD
Paricalcitol—VDR—kidney—kidney cancer	0.00414	0.0573	CbGeAlD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—FOSL2—kidney cancer	0.0041	0.036	CbGpPWpGaD
Paricalcitol—VDR—cortex of kidney—kidney cancer	0.00404	0.0558	CbGeAlD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—CITED1—kidney cancer	0.0035	0.0308	CbGpPWpGaD
Paricalcitol—VDR—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	0.00258	0.0227	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—TFE3—kidney cancer	0.00253	0.0222	CbGpPWpGaD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.00236	0.0207	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—ACY1—kidney cancer	0.00229	0.0201	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—JUND—kidney cancer	0.00205	0.018	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—PIDD1—kidney cancer	0.00192	0.0169	CbGpPWpGaD
Paricalcitol—UGT1A4—Tamoxifen metabolism—CYP1A1—kidney cancer	0.00191	0.0168	CbGpPWpGaD
Paricalcitol—VDR—Ovarian Infertility Genes—EGR1—kidney cancer	0.00183	0.0161	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—ACY1—kidney cancer	0.00183	0.0161	CbGpPWpGaD
Paricalcitol—CYP24A1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	0.00177	0.0155	CbGpPWpGaD
Paricalcitol—CYP3A4—Aflatoxin activation and detoxification—ACY1—kidney cancer	0.00173	0.0152	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—OGG1—kidney cancer	0.00161	0.0141	CbGpPWpGaD
Paricalcitol—UGT1A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	0.00148	0.013	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	0.00148	0.013	CbGpPWpGaD
Paricalcitol—CYP3A4—renal system—kidney cancer	0.00143	0.0198	CbGeAlD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—JUNB—kidney cancer	0.00139	0.0123	CbGpPWpGaD
Paricalcitol—CYP3A4—kidney—kidney cancer	0.00139	0.0191	CbGeAlD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.0013	0.0114	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—ALDH1A1—kidney cancer	0.00125	0.011	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of steroid hormones and vitamin D—POMC—kidney cancer	0.00124	0.0109	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—kidney cancer	0.00118	0.0104	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—NDRG1—kidney cancer	0.0011	0.0097	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—SLC5A3—kidney cancer	0.00109	0.00962	CbGpPWpGaD
Paricalcitol—CYP3A4—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.00109	0.00956	CbGpPWpGaD
Paricalcitol—CYP24A1—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	0.00103	0.00908	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—CYP1A1—kidney cancer	0.00102	0.00897	CbGpPWpGaD
Paricalcitol—CYP24A1—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	0.00102	0.00896	CbGpPWpGaD
Paricalcitol—UGT1A4—Phase II conjugation—GSTT1—kidney cancer	0.00101	0.00884	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—ALDH1A1—kidney cancer	0.001	0.0088	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—KEAP1—kidney cancer	0.000957	0.00841	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—APAF1—kidney cancer	0.000882	0.00775	CbGpPWpGaD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	0.000837	0.00736	CbGpPWpGaD
Paricalcitol—VDR—Ovarian Infertility Genes—CDKN1B—kidney cancer	0.000806	0.00708	CbGpPWpGaD
Paricalcitol—CYP3A4—Aflatoxin B1 metabolism—GSTM1—kidney cancer	0.000788	0.00693	CbGpPWpGaD
Paricalcitol—CYP24A1—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	0.00077	0.00677	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—CDKN2B—kidney cancer	0.000757	0.00665	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—GSTT1—kidney cancer	0.000736	0.00647	CbGpPWpGaD
Paricalcitol—CYP3A4—Codeine and Morphine Metabolism—ABCB1—kidney cancer	0.00073	0.00641	CbGpPWpGaD
Paricalcitol—UGT1A4—Phase II conjugation—GSTP1—kidney cancer	0.000697	0.00613	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—PTGS1—kidney cancer	0.00069	0.00606	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—CTSD—kidney cancer	0.000689	0.00605	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—kidney cancer	0.000669	0.00588	CbGpPWpGaD
Paricalcitol—VDR—Retinoic acid receptors-mediated signaling—MAPK3—kidney cancer	0.000667	0.00587	CbGpPWpGaD
Paricalcitol—UGT1A4—Phase II conjugation—GSTM1—kidney cancer	0.000641	0.00563	CbGpPWpGaD
Paricalcitol—VDR—Retinoic acid receptors-mediated signaling—MAPK1—kidney cancer	0.000635	0.00558	CbGpPWpGaD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—POMC—kidney cancer	0.000624	0.00549	CbGpPWpGaD
Paricalcitol—CYP3A4—Irinotecan Pathway—BCHE—kidney cancer	0.000619	0.00544	CbGpPWpGaD
Paricalcitol—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—kidney cancer	0.000611	0.00537	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	0.000609	0.00535	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—CDKN2A—kidney cancer	0.000599	0.00526	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—GSTT1—kidney cancer	0.000589	0.00517	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—SLC5A5—kidney cancer	0.000577	0.00508	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—CDKN1B—kidney cancer	0.000575	0.00505	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL2—kidney cancer	0.000563	0.00495	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—SLC2A1—kidney cancer	0.000558	0.0049	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—PTGS1—kidney cancer	0.000552	0.00485	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—JUN—kidney cancer	0.000547	0.00481	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—EGR1—kidney cancer	0.000518	0.00455	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—GSTP1—kidney cancer	0.00051	0.00449	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—GSTP1—kidney cancer	0.000503	0.00442	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—GSTM1—kidney cancer	0.000469	0.00412	CbGpPWpGaD
Paricalcitol—CYP3A4—Tryptophan metabolism—ALDH1A1—kidney cancer	0.000467	0.00411	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—GSTP1—kidney cancer	0.000465	0.00409	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—GSTM1—kidney cancer	0.000462	0.00407	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—CYP1A1—kidney cancer	0.000445	0.00391	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—CYP1A1—kidney cancer	0.000438	0.00385	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—GSTM1—kidney cancer	0.000427	0.00376	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—HARS—kidney cancer	0.000421	0.0037	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—GSTP1—kidney cancer	0.000408	0.00359	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—GSTP1—kidney cancer	0.000402	0.00354	CbGpPWpGaD
Paricalcitol—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	0.000399	0.00351	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ACY1—kidney cancer	0.000391	0.00344	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—TSC2—kidney cancer	0.00039	0.00342	CbGpPWpGaD
Paricalcitol—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	0.000386	0.00339	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—GSTM1—kidney cancer	0.000375	0.0033	CbGpPWpGaD
Paricalcitol—CYP3A4—Estrogen metabolism—GSTM1—kidney cancer	0.00037	0.00325	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—GSTM1—kidney cancer	0.00037	0.00325	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—MET—kidney cancer	0.000365	0.00321	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—JUN—kidney cancer	0.000365	0.00321	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—EIF5B—kidney cancer	0.000358	0.00315	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—CYP1A1—kidney cancer	0.000355	0.00312	CbGpPWpGaD
Paricalcitol—CYP3A4—Estrogen metabolism—CYP1A1—kidney cancer	0.000351	0.00309	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—CYP1A1—kidney cancer	0.000351	0.00308	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—APC—kidney cancer	0.000344	0.00302	CbGpPWpGaD
Paricalcitol—CYP3A4—Irinotecan Pathway—APC—kidney cancer	0.000336	0.00296	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	0.000333	0.00293	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PDHB—kidney cancer	0.000332	0.00292	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—POMC—kidney cancer	0.000331	0.00291	CbGpPWpGaD
Paricalcitol—CYP3A4—Xenobiotics—CYP1A1—kidney cancer	0.000323	0.00284	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ACY1—kidney cancer	0.000313	0.00275	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CCBL1—kidney cancer	0.000313	0.00275	CbGpPWpGaD
Paricalcitol—CYP3A4—Tamoxifen metabolism—CYP1A1—kidney cancer	0.00031	0.00273	CbGpPWpGaD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.000306	0.00269	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—ACY1—kidney cancer	0.000297	0.00261	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—MYC—kidney cancer	0.000293	0.00258	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	0.000283	0.00249	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PPAT—kidney cancer	0.000271	0.00238	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GLIPR1—kidney cancer	0.000271	0.00238	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	0.000268	0.00235	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PDHB—kidney cancer	0.000266	0.00234	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—POMC—kidney cancer	0.000265	0.00233	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	0.000265	0.00233	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—FH—kidney cancer	0.000252	0.00222	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—APRT—kidney cancer	0.000252	0.00222	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CCBL1—kidney cancer	0.00025	0.0022	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	0.000246	0.00217	CbGpPWpGaD
Paricalcitol—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	0.000241	0.00212	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GPC3—kidney cancer	0.000237	0.00208	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—JUN—kidney cancer	0.000236	0.00207	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—JUNB—kidney cancer	0.000232	0.00204	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—EEF2—kidney cancer	0.000231	0.00203	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CA2—kidney cancer	0.00023	0.00203	CbGpPWpGaD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	0.000229	0.00202	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—PTEN—kidney cancer	0.000228	0.002	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ALAD—kidney cancer	0.000225	0.00197	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—TET2—kidney cancer	0.000221	0.00195	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ST3GAL2—kidney cancer	0.000219	0.00193	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GLIPR1—kidney cancer	0.000217	0.0019	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PPAT—kidney cancer	0.000217	0.0019	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ALDH1A1—kidney cancer	0.000214	0.00188	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PGK1—kidney cancer	0.000205	0.00181	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—SLC5A3—kidney cancer	0.000205	0.00181	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—TCEB1—kidney cancer	0.000202	0.00178	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—TCEB2—kidney cancer	0.000202	0.00178	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—APRT—kidney cancer	0.000201	0.00177	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—LDHB—kidney cancer	0.000201	0.00177	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—FH—kidney cancer	0.000201	0.00177	CbGpPWpGaD
Paricalcitol—Somnolence—Gemcitabine—kidney cancer	0.000201	0.000443	CcSEcCtD
Paricalcitol—Nausea—Everolimus—kidney cancer	0.0002	0.000442	CcSEcCtD
Paricalcitol—Diarrhoea—Sorafenib—kidney cancer	0.0002	0.000442	CcSEcCtD
Paricalcitol—Hypertension—Paclitaxel—kidney cancer	0.0002	0.000441	CcSEcCtD
Paricalcitol—Pruritus—Sunitinib—kidney cancer	0.000199	0.000439	CcSEcCtD
Paricalcitol—Angiopathy—Capecitabine—kidney cancer	0.000198	0.000437	CcSEcCtD
Paricalcitol—Immune system disorder—Capecitabine—kidney cancer	0.000197	0.000435	CcSEcCtD
Paricalcitol—Myalgia—Paclitaxel—kidney cancer	0.000197	0.000435	CcSEcCtD
Paricalcitol—Chest pain—Paclitaxel—kidney cancer	0.000197	0.000435	CcSEcCtD
Paricalcitol—Arthralgia—Paclitaxel—kidney cancer	0.000197	0.000435	CcSEcCtD
Paricalcitol—Mediastinal disorder—Capecitabine—kidney cancer	0.000197	0.000434	CcSEcCtD
Paricalcitol—Anxiety—Paclitaxel—kidney cancer	0.000197	0.000434	CcSEcCtD
Paricalcitol—Decreased appetite—Gemcitabine—kidney cancer	0.000196	0.000433	CcSEcCtD
Paricalcitol—Hypersensitivity—Dactinomycin—kidney cancer	0.000196	0.000433	CcSEcCtD
Paricalcitol—Chills—Capecitabine—kidney cancer	0.000196	0.000432	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000196	0.000432	CcSEcCtD
Paricalcitol—Arrhythmia—Capecitabine—kidney cancer	0.000195	0.00043	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000195	0.00043	CcSEcCtD
Paricalcitol—Discomfort—Paclitaxel—kidney cancer	0.000195	0.00043	CcSEcCtD
Paricalcitol—Fatigue—Gemcitabine—kidney cancer	0.000195	0.00043	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Vincristine—kidney cancer	0.000195	0.000429	CcSEcCtD
Paricalcitol—Cardiac arrest—Doxorubicin—kidney cancer	0.000194	0.000427	CcSEcCtD
Paricalcitol—Dizziness—Sorafenib—kidney cancer	0.000194	0.000427	CcSEcCtD
Paricalcitol—Pain—Gemcitabine—kidney cancer	0.000193	0.000426	CcSEcCtD
Paricalcitol—Constipation—Gemcitabine—kidney cancer	0.000193	0.000426	CcSEcCtD
Paricalcitol—Nausea—Erlotinib—kidney cancer	0.000193	0.000426	CcSEcCtD
Paricalcitol—Alopecia—Capecitabine—kidney cancer	0.000193	0.000426	CcSEcCtD
Paricalcitol—Dry mouth—Paclitaxel—kidney cancer	0.000193	0.000426	CcSEcCtD
Paricalcitol—Diarrhoea—Sunitinib—kidney cancer	0.000193	0.000425	CcSEcCtD
Paricalcitol—Mental disorder—Capecitabine—kidney cancer	0.000191	0.000422	CcSEcCtD
Paricalcitol—Asthenia—Dactinomycin—kidney cancer	0.000191	0.000422	CcSEcCtD
Paricalcitol—Confusional state—Paclitaxel—kidney cancer	0.000191	0.000421	CcSEcCtD
Paricalcitol—Malnutrition—Capecitabine—kidney cancer	0.00019	0.000419	CcSEcCtD
Paricalcitol—Dehydration—Doxorubicin—kidney cancer	0.000189	0.000418	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—GPC3—kidney cancer	0.000189	0.00166	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—CDKN2B—kidney cancer	0.000189	0.00166	CbGpPWpGaD
Paricalcitol—Oedema—Paclitaxel—kidney cancer	0.000189	0.000417	CcSEcCtD
Paricalcitol—Body temperature increased—Vincristine—kidney cancer	0.000188	0.000415	CcSEcCtD
Paricalcitol—Abdominal pain—Vincristine—kidney cancer	0.000188	0.000415	CcSEcCtD
Paricalcitol—Infection—Paclitaxel—kidney cancer	0.000188	0.000414	CcSEcCtD
Paricalcitol—Dysgeusia—Capecitabine—kidney cancer	0.000186	0.000411	CcSEcCtD
Paricalcitol—Dizziness—Sunitinib—kidney cancer	0.000186	0.000411	CcSEcCtD
Paricalcitol—Feeling abnormal—Gemcitabine—kidney cancer	0.000186	0.000411	CcSEcCtD
Paricalcitol—Shock—Paclitaxel—kidney cancer	0.000186	0.00041	CcSEcCtD
Paricalcitol—Vomiting—Sorafenib—kidney cancer	0.000186	0.00041	CcSEcCtD
Paricalcitol—Nervous system disorder—Paclitaxel—kidney cancer	0.000186	0.000409	CcSEcCtD
Paricalcitol—Rash—Sorafenib—kidney cancer	0.000185	0.000407	CcSEcCtD
Paricalcitol—Dermatitis—Sorafenib—kidney cancer	0.000184	0.000407	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—CA2—kidney cancer	0.000184	0.00162	CbGpPWpGaD
Paricalcitol—Back pain—Capecitabine—kidney cancer	0.000184	0.000406	CcSEcCtD
Paricalcitol—Breast disorder—Doxorubicin—kidney cancer	0.000184	0.000406	CcSEcCtD
Paricalcitol—Skin disorder—Paclitaxel—kidney cancer	0.000184	0.000405	CcSEcCtD
Paricalcitol—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.000183	0.000404	CcSEcCtD
Paricalcitol—Headache—Sorafenib—kidney cancer	0.000183	0.000404	CcSEcCtD
Paricalcitol—Muscle spasms—Capecitabine—kidney cancer	0.000183	0.000403	CcSEcCtD
Paricalcitol—Hyperhidrosis—Paclitaxel—kidney cancer	0.000183	0.000403	CcSEcCtD
Paricalcitol—Diarrhoea—Dactinomycin—kidney cancer	0.000182	0.000402	CcSEcCtD
Paricalcitol—Nasopharyngitis—Doxorubicin—kidney cancer	0.000182	0.000401	CcSEcCtD
Paricalcitol—Anorexia—Paclitaxel—kidney cancer	0.00018	0.000398	CcSEcCtD
Paricalcitol—Gastritis—Doxorubicin—kidney cancer	0.00018	0.000397	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—ALAD—kidney cancer	0.00018	0.00158	CbGpPWpGaD
Paricalcitol—Vomiting—Sunitinib—kidney cancer	0.000179	0.000395	CcSEcCtD
Paricalcitol—Body temperature increased—Gemcitabine—kidney cancer	0.000179	0.000394	CcSEcCtD
Paricalcitol—Rash—Sunitinib—kidney cancer	0.000178	0.000392	CcSEcCtD
Paricalcitol—Dermatitis—Sunitinib—kidney cancer	0.000177	0.000391	CcSEcCtD
Paricalcitol—Hypotension—Paclitaxel—kidney cancer	0.000177	0.00039	CcSEcCtD
Paricalcitol—Ill-defined disorder—Capecitabine—kidney cancer	0.000177	0.000389	CcSEcCtD
Paricalcitol—Headache—Sunitinib—kidney cancer	0.000176	0.000389	CcSEcCtD
Paricalcitol—Asthma—Doxorubicin—kidney cancer	0.000176	0.000388	CcSEcCtD
Paricalcitol—Dysphagia—Doxorubicin—kidney cancer	0.000176	0.000388	CcSEcCtD
Paricalcitol—Influenza—Doxorubicin—kidney cancer	0.000176	0.000388	CcSEcCtD
Paricalcitol—Anaemia—Capecitabine—kidney cancer	0.000176	0.000388	CcSEcCtD
Paricalcitol—Hypersensitivity—Vincristine—kidney cancer	0.000176	0.000387	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—ST3GAL2—kidney cancer	0.000175	0.00154	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CA9—kidney cancer	0.000175	0.00154	CbGpPWpGaD
Paricalcitol—Nausea—Sorafenib—kidney cancer	0.000174	0.000383	CcSEcCtD
Paricalcitol—Pancreatitis—Doxorubicin—kidney cancer	0.000173	0.00038	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000172	0.00038	CcSEcCtD
Paricalcitol—Malaise—Capecitabine—kidney cancer	0.000172	0.000378	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—ALDH1A1—kidney cancer	0.000171	0.00151	CbGpPWpGaD
Paricalcitol—Insomnia—Paclitaxel—kidney cancer	0.000171	0.000377	CcSEcCtD
Paricalcitol—Vertigo—Capecitabine—kidney cancer	0.000171	0.000377	CcSEcCtD
Paricalcitol—Asthenia—Vincristine—kidney cancer	0.000171	0.000377	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	0.000171	0.0015	CbGpPWpGaD
Paricalcitol—Syncope—Capecitabine—kidney cancer	0.000171	0.000376	CcSEcCtD
Paricalcitol—Leukopenia—Capecitabine—kidney cancer	0.00017	0.000375	CcSEcCtD
Paricalcitol—Paraesthesia—Paclitaxel—kidney cancer	0.00017	0.000375	CcSEcCtD
Paricalcitol—Vomiting—Dactinomycin—kidney cancer	0.00017	0.000374	CcSEcCtD
Paricalcitol—Dyspnoea—Paclitaxel—kidney cancer	0.000169	0.000372	CcSEcCtD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.000169	0.00148	CbGpPWpGaD
Paricalcitol—Somnolence—Paclitaxel—kidney cancer	0.000168	0.000371	CcSEcCtD
Paricalcitol—Palpitations—Capecitabine—kidney cancer	0.000168	0.000371	CcSEcCtD
Paricalcitol—Rash—Dactinomycin—kidney cancer	0.000168	0.000371	CcSEcCtD
Paricalcitol—Nausea—Sunitinib—kidney cancer	0.000167	0.000369	CcSEcCtD
Paricalcitol—Loss of consciousness—Capecitabine—kidney cancer	0.000167	0.000369	CcSEcCtD
Paricalcitol—Dyspepsia—Paclitaxel—kidney cancer	0.000167	0.000367	CcSEcCtD
Paricalcitol—Cough—Capecitabine—kidney cancer	0.000166	0.000366	CcSEcCtD
Paricalcitol—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	0.000166	0.00146	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—RPL14—kidney cancer	0.000165	0.00145	CbGpPWpGaD
Paricalcitol—Decreased appetite—Paclitaxel—kidney cancer	0.000164	0.000363	CcSEcCtD
Paricalcitol—Hypertension—Capecitabine—kidney cancer	0.000164	0.000362	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—SLC5A3—kidney cancer	0.000164	0.00144	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PGK1—kidney cancer	0.000164	0.00144	CbGpPWpGaD
Paricalcitol—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000164	0.000361	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000163	0.00036	CcSEcCtD
Paricalcitol—Fatigue—Paclitaxel—kidney cancer	0.000163	0.00036	CcSEcCtD
Paricalcitol—Diarrhoea—Vincristine—kidney cancer	0.000163	0.000359	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	0.000163	0.00143	CbGpPWpGaD
Paricalcitol—Asthenia—Gemcitabine—kidney cancer	0.000162	0.000357	CcSEcCtD
Paricalcitol—Arthralgia—Capecitabine—kidney cancer	0.000162	0.000357	CcSEcCtD
Paricalcitol—Chest pain—Capecitabine—kidney cancer	0.000162	0.000357	CcSEcCtD
Paricalcitol—Myalgia—Capecitabine—kidney cancer	0.000162	0.000357	CcSEcCtD
Paricalcitol—Pain—Paclitaxel—kidney cancer	0.000162	0.000357	CcSEcCtD
Paricalcitol—Constipation—Paclitaxel—kidney cancer	0.000162	0.000357	CcSEcCtD
Paricalcitol—Anxiety—Capecitabine—kidney cancer	0.000161	0.000356	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—LDHB—kidney cancer	0.000161	0.00142	CbGpPWpGaD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000161	0.000355	CcSEcCtD
Paricalcitol—Discomfort—Capecitabine—kidney cancer	0.00016	0.000353	CcSEcCtD
Paricalcitol—Pruritus—Gemcitabine—kidney cancer	0.00016	0.000353	CcSEcCtD
Paricalcitol—Weight decreased—Doxorubicin—kidney cancer	0.000159	0.000351	CcSEcCtD
Paricalcitol—Dry mouth—Capecitabine—kidney cancer	0.000158	0.000349	CcSEcCtD
Paricalcitol—Nausea—Dactinomycin—kidney cancer	0.000158	0.000349	CcSEcCtD
Paricalcitol—Pneumonia—Doxorubicin—kidney cancer	0.000158	0.000348	CcSEcCtD
Paricalcitol—Dizziness—Vincristine—kidney cancer	0.000158	0.000347	CcSEcCtD
Paricalcitol—Infestation—Doxorubicin—kidney cancer	0.000157	0.000346	CcSEcCtD
Paricalcitol—Infestation NOS—Doxorubicin—kidney cancer	0.000157	0.000346	CcSEcCtD
Paricalcitol—Confusional state—Capecitabine—kidney cancer	0.000157	0.000345	CcSEcCtD
Paricalcitol—Feeling abnormal—Paclitaxel—kidney cancer	0.000156	0.000344	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—TP53—kidney cancer	0.000155	0.00137	CbGpPWpGaD
Paricalcitol—Oedema—Capecitabine—kidney cancer	0.000155	0.000342	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000155	0.000341	CcSEcCtD
Paricalcitol—Diarrhoea—Gemcitabine—kidney cancer	0.000155	0.000341	CcSEcCtD
Paricalcitol—Infection—Capecitabine—kidney cancer	0.000154	0.00034	CcSEcCtD
Paricalcitol—Shock—Capecitabine—kidney cancer	0.000153	0.000337	CcSEcCtD
Paricalcitol—Conjunctivitis—Doxorubicin—kidney cancer	0.000153	0.000336	CcSEcCtD
Paricalcitol—Urinary tract infection—Doxorubicin—kidney cancer	0.000153	0.000336	CcSEcCtD
Paricalcitol—Nervous system disorder—Capecitabine—kidney cancer	0.000152	0.000336	CcSEcCtD
Paricalcitol—Vomiting—Vincristine—kidney cancer	0.000151	0.000334	CcSEcCtD
Paricalcitol—Skin disorder—Capecitabine—kidney cancer	0.000151	0.000333	CcSEcCtD
Paricalcitol—Sweating—Doxorubicin—kidney cancer	0.00015	0.000332	CcSEcCtD
Paricalcitol—Urticaria—Paclitaxel—kidney cancer	0.00015	0.000331	CcSEcCtD
Paricalcitol—Rash—Vincristine—kidney cancer	0.00015	0.000331	CcSEcCtD
Paricalcitol—Hyperhidrosis—Capecitabine—kidney cancer	0.00015	0.000331	CcSEcCtD
Paricalcitol—Dermatitis—Vincristine—kidney cancer	0.00015	0.000331	CcSEcCtD
Paricalcitol—Abdominal pain—Paclitaxel—kidney cancer	0.00015	0.00033	CcSEcCtD
Paricalcitol—Body temperature increased—Paclitaxel—kidney cancer	0.00015	0.00033	CcSEcCtD
Paricalcitol—Headache—Vincristine—kidney cancer	0.000149	0.000329	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—CRABP1—kidney cancer	0.000149	0.00131	CbGpPWpGaD
Paricalcitol—Epistaxis—Doxorubicin—kidney cancer	0.000148	0.000326	CcSEcCtD
Paricalcitol—Anorexia—Capecitabine—kidney cancer	0.000148	0.000326	CcSEcCtD
Paricalcitol—Sinusitis—Doxorubicin—kidney cancer	0.000147	0.000325	CcSEcCtD
Paricalcitol—Hypotension—Capecitabine—kidney cancer	0.000145	0.00032	CcSEcCtD
Paricalcitol—Vomiting—Gemcitabine—kidney cancer	0.000144	0.000317	CcSEcCtD
Paricalcitol—Rash—Gemcitabine—kidney cancer	0.000143	0.000314	CcSEcCtD
Paricalcitol—Dermatitis—Gemcitabine—kidney cancer	0.000142	0.000314	CcSEcCtD
Paricalcitol—Headache—Gemcitabine—kidney cancer	0.000142	0.000312	CcSEcCtD
Paricalcitol—Nausea—Vincristine—kidney cancer	0.000142	0.000312	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000141	0.000312	CcSEcCtD
Paricalcitol—Insomnia—Capecitabine—kidney cancer	0.00014	0.00031	CcSEcCtD
Paricalcitol—Hypoaesthesia—Doxorubicin—kidney cancer	0.00014	0.000309	CcSEcCtD
Paricalcitol—Pharyngitis—Doxorubicin—kidney cancer	0.00014	0.000308	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—CA9—kidney cancer	0.00014	0.00123	CbGpPWpGaD
Paricalcitol—Paraesthesia—Capecitabine—kidney cancer	0.000139	0.000307	CcSEcCtD
Paricalcitol—Hypersensitivity—Paclitaxel—kidney cancer	0.000139	0.000307	CcSEcCtD
Paricalcitol—Urinary tract disorder—Doxorubicin—kidney cancer	0.000139	0.000307	CcSEcCtD
Paricalcitol—Oedema peripheral—Doxorubicin—kidney cancer	0.000139	0.000306	CcSEcCtD
Paricalcitol—Connective tissue disorder—Doxorubicin—kidney cancer	0.000138	0.000305	CcSEcCtD
Paricalcitol—Dyspnoea—Capecitabine—kidney cancer	0.000138	0.000305	CcSEcCtD
Paricalcitol—Urethral disorder—Doxorubicin—kidney cancer	0.000138	0.000304	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—ITPR2—kidney cancer	0.000138	0.00121	CbGpPWpGaD
Paricalcitol—Dyspepsia—Capecitabine—kidney cancer	0.000137	0.000301	CcSEcCtD
Paricalcitol—Asthenia—Paclitaxel—kidney cancer	0.000136	0.000299	CcSEcCtD
Paricalcitol—Decreased appetite—Capecitabine—kidney cancer	0.000135	0.000298	CcSEcCtD
Paricalcitol—Nausea—Gemcitabine—kidney cancer	0.000134	0.000296	CcSEcCtD
Paricalcitol—VDR—Gene Expression—HSPB1—kidney cancer	0.000134	0.00118	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—EIF4EBP1—kidney cancer	0.000134	0.00118	CbGpPWpGaD
Paricalcitol—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000134	0.000296	CcSEcCtD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	0.000134	0.00118	CbGpPWpGaD
Paricalcitol—Fatigue—Capecitabine—kidney cancer	0.000134	0.000295	CcSEcCtD
Paricalcitol—Pruritus—Paclitaxel—kidney cancer	0.000134	0.000295	CcSEcCtD
Paricalcitol—Pain—Capecitabine—kidney cancer	0.000133	0.000293	CcSEcCtD
Paricalcitol—Constipation—Capecitabine—kidney cancer	0.000133	0.000293	CcSEcCtD
Paricalcitol—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	0.000132	0.00116	CbGpPWpGaD
Paricalcitol—Eye disorder—Doxorubicin—kidney cancer	0.000132	0.00029	CcSEcCtD
Paricalcitol—Cardiac disorder—Doxorubicin—kidney cancer	0.000131	0.000288	CcSEcCtD
Paricalcitol—Diarrhoea—Paclitaxel—kidney cancer	0.000129	0.000285	CcSEcCtD
Paricalcitol—Feeling abnormal—Capecitabine—kidney cancer	0.000128	0.000282	CcSEcCtD
Paricalcitol—Angiopathy—Doxorubicin—kidney cancer	0.000128	0.000282	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—POMC—kidney cancer	0.000127	0.00112	CbGpPWpGaD
Paricalcitol—Immune system disorder—Doxorubicin—kidney cancer	0.000127	0.000281	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Capecitabine—kidney cancer	0.000127	0.00028	CcSEcCtD
Paricalcitol—Mediastinal disorder—Doxorubicin—kidney cancer	0.000127	0.00028	CcSEcCtD
Paricalcitol—Chills—Doxorubicin—kidney cancer	0.000126	0.000279	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—ACHE—kidney cancer	0.000126	0.00111	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GSTT1—kidney cancer	0.000126	0.00111	CbGpPWpGaD
Paricalcitol—Arrhythmia—Doxorubicin—kidney cancer	0.000126	0.000277	CcSEcCtD
Paricalcitol—Dizziness—Paclitaxel—kidney cancer	0.000125	0.000276	CcSEcCtD
Paricalcitol—VDR—Gene Expression—PSMD7—kidney cancer	0.000125	0.0011	CbGpPWpGaD
Paricalcitol—Alopecia—Doxorubicin—kidney cancer	0.000125	0.000274	CcSEcCtD
Paricalcitol—Mental disorder—Doxorubicin—kidney cancer	0.000123	0.000272	CcSEcCtD
Paricalcitol—Urticaria—Capecitabine—kidney cancer	0.000123	0.000272	CcSEcCtD
Paricalcitol—Abdominal pain—Capecitabine—kidney cancer	0.000123	0.000271	CcSEcCtD
Paricalcitol—Body temperature increased—Capecitabine—kidney cancer	0.000123	0.000271	CcSEcCtD
Paricalcitol—Malnutrition—Doxorubicin—kidney cancer	0.000123	0.00027	CcSEcCtD
Paricalcitol—Tension—Doxorubicin—kidney cancer	0.00012	0.000265	CcSEcCtD
Paricalcitol—Vomiting—Paclitaxel—kidney cancer	0.00012	0.000265	CcSEcCtD
Paricalcitol—Dysgeusia—Doxorubicin—kidney cancer	0.00012	0.000265	CcSEcCtD
Paricalcitol—Rash—Paclitaxel—kidney cancer	0.000119	0.000263	CcSEcCtD
Paricalcitol—Dermatitis—Paclitaxel—kidney cancer	0.000119	0.000263	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—SCARB1—kidney cancer	0.000119	0.00105	CbGpPWpGaD
Paricalcitol—Nervousness—Doxorubicin—kidney cancer	0.000119	0.000263	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—CRABP1—kidney cancer	0.000119	0.00104	CbGpPWpGaD
Paricalcitol—Back pain—Doxorubicin—kidney cancer	0.000119	0.000262	CcSEcCtD
Paricalcitol—Headache—Paclitaxel—kidney cancer	0.000119	0.000261	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—PTGS1—kidney cancer	0.000118	0.00104	CbGpPWpGaD
Paricalcitol—Muscle spasms—Doxorubicin—kidney cancer	0.000118	0.00026	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—PSMD7—kidney cancer	0.000116	0.00102	CbGpPWpGaD
Paricalcitol—Hypersensitivity—Capecitabine—kidney cancer	0.000114	0.000252	CcSEcCtD
Paricalcitol—Ill-defined disorder—Doxorubicin—kidney cancer	0.000114	0.000251	CcSEcCtD
Paricalcitol—Anaemia—Doxorubicin—kidney cancer	0.000113	0.00025	CcSEcCtD
Paricalcitol—Agitation—Doxorubicin—kidney cancer	0.000113	0.000248	CcSEcCtD
Paricalcitol—Nausea—Paclitaxel—kidney cancer	0.000112	0.000248	CcSEcCtD
Paricalcitol—VDR—Gene Expression—JUNB—kidney cancer	0.000112	0.000984	CbGpPWpGaD
Paricalcitol—Asthenia—Capecitabine—kidney cancer	0.000111	0.000246	CcSEcCtD
Paricalcitol—Malaise—Doxorubicin—kidney cancer	0.000111	0.000244	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—ITPR2—kidney cancer	0.00011	0.00097	CbGpPWpGaD
Paricalcitol—Vertigo—Doxorubicin—kidney cancer	0.00011	0.000243	CcSEcCtD
Paricalcitol—Syncope—Doxorubicin—kidney cancer	0.00011	0.000242	CcSEcCtD
Paricalcitol—Pruritus—Capecitabine—kidney cancer	0.00011	0.000242	CcSEcCtD
Paricalcitol—Leukopenia—Doxorubicin—kidney cancer	0.00011	0.000242	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—BCHE—kidney cancer	0.00011	0.000964	CbGpPWpGaD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	0.000109	0.000955	CbGpPWpGaD
Paricalcitol—Palpitations—Doxorubicin—kidney cancer	0.000108	0.000239	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—SLC5A5—kidney cancer	0.000108	0.000952	CbGpPWpGaD
Paricalcitol—Loss of consciousness—Doxorubicin—kidney cancer	0.000108	0.000238	CcSEcCtD
Paricalcitol—Cough—Doxorubicin—kidney cancer	0.000107	0.000236	CcSEcCtD
Paricalcitol—Diarrhoea—Capecitabine—kidney cancer	0.000106	0.000234	CcSEcCtD
Paricalcitol—Hypertension—Doxorubicin—kidney cancer	0.000106	0.000233	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—SLC2A1—kidney cancer	0.000105	0.00092	CbGpPWpGaD
Paricalcitol—Arthralgia—Doxorubicin—kidney cancer	0.000104	0.00023	CcSEcCtD
Paricalcitol—Chest pain—Doxorubicin—kidney cancer	0.000104	0.00023	CcSEcCtD
Paricalcitol—Myalgia—Doxorubicin—kidney cancer	0.000104	0.00023	CcSEcCtD
Paricalcitol—Anxiety—Doxorubicin—kidney cancer	0.000104	0.000229	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000104	0.000229	CcSEcCtD
Paricalcitol—Discomfort—Doxorubicin—kidney cancer	0.000103	0.000227	CcSEcCtD
Paricalcitol—Dizziness—Capecitabine—kidney cancer	0.000103	0.000226	CcSEcCtD
Paricalcitol—Dry mouth—Doxorubicin—kidney cancer	0.000102	0.000225	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	0.000102	0.000892	CbGpPWpGaD
Paricalcitol—Confusional state—Doxorubicin—kidney cancer	0.000101	0.000223	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—GSTT1—kidney cancer	0.000101	0.000885	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ACHE—kidney cancer	0.000101	0.000885	CbGpPWpGaD
Paricalcitol—Oedema—Doxorubicin—kidney cancer	0.0001	0.000221	CcSEcCtD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	9.99e-05	0.000878	CbGpPWpGaD
Paricalcitol—Infection—Doxorubicin—kidney cancer	9.94e-05	0.000219	CcSEcCtD
Paricalcitol—Vomiting—Capecitabine—kidney cancer	9.87e-05	0.000218	CcSEcCtD
Paricalcitol—Shock—Doxorubicin—kidney cancer	9.85e-05	0.000217	CcSEcCtD
Paricalcitol—Nervous system disorder—Doxorubicin—kidney cancer	9.82e-05	0.000216	CcSEcCtD
Paricalcitol—Rash—Capecitabine—kidney cancer	9.79e-05	0.000216	CcSEcCtD
Paricalcitol—Dermatitis—Capecitabine—kidney cancer	9.78e-05	0.000216	CcSEcCtD
Paricalcitol—Headache—Capecitabine—kidney cancer	9.73e-05	0.000214	CcSEcCtD
Paricalcitol—Skin disorder—Doxorubicin—kidney cancer	9.72e-05	0.000214	CcSEcCtD
Paricalcitol—Hyperhidrosis—Doxorubicin—kidney cancer	9.68e-05	0.000213	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—GSTT1—kidney cancer	9.55e-05	0.00084	CbGpPWpGaD
Paricalcitol—Anorexia—Doxorubicin—kidney cancer	9.54e-05	0.00021	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—SCARB1—kidney cancer	9.53e-05	0.000838	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PTGS1—kidney cancer	9.43e-05	0.000829	CbGpPWpGaD
Paricalcitol—Hypotension—Doxorubicin—kidney cancer	9.35e-05	0.000206	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—PSMD7—kidney cancer	9.25e-05	0.000813	CbGpPWpGaD
Paricalcitol—Nausea—Capecitabine—kidney cancer	9.22e-05	0.000203	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Doxorubicin—kidney cancer	9.12e-05	0.000201	CcSEcCtD
Paricalcitol—VDR—Gene Expression—CDKN2B—kidney cancer	9.11e-05	0.000801	CbGpPWpGaD
Paricalcitol—Insomnia—Doxorubicin—kidney cancer	9.05e-05	0.0002	CcSEcCtD
Paricalcitol—Paraesthesia—Doxorubicin—kidney cancer	8.99e-05	0.000198	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—PTGS1—kidney cancer	8.95e-05	0.000787	CbGpPWpGaD
Paricalcitol—Dyspnoea—Doxorubicin—kidney cancer	8.92e-05	0.000197	CcSEcCtD
Paricalcitol—Somnolence—Doxorubicin—kidney cancer	8.9e-05	0.000196	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	8.85e-05	0.000778	CbGpPWpGaD
Paricalcitol—Dyspepsia—Doxorubicin—kidney cancer	8.81e-05	0.000194	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—BCHE—kidney cancer	8.77e-05	0.000771	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GSTP1—kidney cancer	8.73e-05	0.000767	CbGpPWpGaD
Paricalcitol—Decreased appetite—Doxorubicin—kidney cancer	8.7e-05	0.000192	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—SLC5A5—kidney cancer	8.66e-05	0.000761	CbGpPWpGaD
Paricalcitol—Gastrointestinal disorder—Doxorubicin—kidney cancer	8.64e-05	0.000191	CcSEcCtD
Paricalcitol—Fatigue—Doxorubicin—kidney cancer	8.63e-05	0.00019	CcSEcCtD
Paricalcitol—Pain—Doxorubicin—kidney cancer	8.56e-05	0.000189	CcSEcCtD
Paricalcitol—Constipation—Doxorubicin—kidney cancer	8.56e-05	0.000189	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—SLC2A1—kidney cancer	8.36e-05	0.000735	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ABCB1—kidney cancer	8.26e-05	0.000726	CbGpPWpGaD
Paricalcitol—Feeling abnormal—Doxorubicin—kidney cancer	8.25e-05	0.000182	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Doxorubicin—kidney cancer	8.19e-05	0.00018	CcSEcCtD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	8.1e-05	0.000712	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GSTM1—kidney cancer	8.02e-05	0.000705	CbGpPWpGaD
Paricalcitol—Urticaria—Doxorubicin—kidney cancer	7.95e-05	0.000175	CcSEcCtD
Paricalcitol—Body temperature increased—Doxorubicin—kidney cancer	7.91e-05	0.000174	CcSEcCtD
Paricalcitol—Abdominal pain—Doxorubicin—kidney cancer	7.91e-05	0.000174	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—CYP1A1—kidney cancer	7.6e-05	0.000668	CbGpPWpGaD
Paricalcitol—Hypersensitivity—Doxorubicin—kidney cancer	7.37e-05	0.000163	CcSEcCtD
Paricalcitol—VDR—Generic Transcription Pathway—MYC—kidney cancer	7.33e-05	0.000645	CbGpPWpGaD
Paricalcitol—Asthenia—Doxorubicin—kidney cancer	7.18e-05	0.000158	CcSEcCtD
Paricalcitol—Pruritus—Doxorubicin—kidney cancer	7.08e-05	0.000156	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—GSTP1—kidney cancer	6.98e-05	0.000613	CbGpPWpGaD
Paricalcitol—Diarrhoea—Doxorubicin—kidney cancer	6.85e-05	0.000151	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—GSTP1—kidney cancer	6.62e-05	0.000582	CbGpPWpGaD
Paricalcitol—Dizziness—Doxorubicin—kidney cancer	6.62e-05	0.000146	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—ABCB1—kidney cancer	6.6e-05	0.000581	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	6.53e-05	0.000574	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GSTM1—kidney cancer	6.41e-05	0.000564	CbGpPWpGaD
Paricalcitol—Vomiting—Doxorubicin—kidney cancer	6.36e-05	0.00014	CcSEcCtD
Paricalcitol—Rash—Doxorubicin—kidney cancer	6.31e-05	0.000139	CcSEcCtD
Paricalcitol—Dermatitis—Doxorubicin—kidney cancer	6.31e-05	0.000139	CcSEcCtD
Paricalcitol—Headache—Doxorubicin—kidney cancer	6.27e-05	0.000138	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6.25e-05	0.000549	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—GSTM1—kidney cancer	6.09e-05	0.000535	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP1A1—kidney cancer	6.08e-05	0.000534	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	6e-05	0.000528	CbGpPWpGaD
Paricalcitol—Nausea—Doxorubicin—kidney cancer	5.95e-05	0.000131	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	5.77e-05	0.000507	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	5.69e-05	0.0005	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—POMC—kidney cancer	5.67e-05	0.000498	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ACY1—kidney cancer	5.07e-05	0.000446	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—POMC—kidney cancer	4.53e-05	0.000398	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PTGS2—kidney cancer	4.52e-05	0.000397	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PDHB—kidney cancer	4.31e-05	0.000379	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—POMC—kidney cancer	4.3e-05	0.000378	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CCBL1—kidney cancer	4.06e-05	0.000357	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PTEN—kidney cancer	3.94e-05	0.000347	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—MAPK3—kidney cancer	3.63e-05	0.000319	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PTGS2—kidney cancer	3.61e-05	0.000318	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—MYC—kidney cancer	3.53e-05	0.00031	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PPAT—kidney cancer	3.52e-05	0.000309	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GLIPR1—kidney cancer	3.52e-05	0.000309	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—FH—kidney cancer	3.27e-05	0.000287	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—APRT—kidney cancer	3.27e-05	0.000287	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PTEN—kidney cancer	3.15e-05	0.000277	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GPC3—kidney cancer	3.07e-05	0.00027	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CA2—kidney cancer	2.99e-05	0.000263	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ALAD—kidney cancer	2.91e-05	0.000256	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ST3GAL2—kidney cancer	2.84e-05	0.00025	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PIK3CA—kidney cancer	2.78e-05	0.000245	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ALDH1A1—kidney cancer	2.78e-05	0.000244	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PGK1—kidney cancer	2.67e-05	0.000234	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SLC5A3—kidney cancer	2.67e-05	0.000234	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—LDHB—kidney cancer	2.61e-05	0.00023	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CA9—kidney cancer	2.27e-05	0.000199	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PIK3CA—kidney cancer	2.22e-05	0.000195	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CRABP1—kidney cancer	1.93e-05	0.000169	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ITPR2—kidney cancer	1.79e-05	0.000158	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ACHE—kidney cancer	1.63e-05	0.000144	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTT1—kidney cancer	1.63e-05	0.000144	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SCARB1—kidney cancer	1.55e-05	0.000136	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PTGS1—kidney cancer	1.53e-05	0.000135	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PSMD7—kidney cancer	1.5e-05	0.000132	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—BCHE—kidney cancer	1.42e-05	0.000125	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.41e-05	0.000124	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SLC2A1—kidney cancer	1.36e-05	0.000119	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTP1—kidney cancer	1.13e-05	9.96e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ABCB1—kidney cancer	1.07e-05	9.42e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTM1—kidney cancer	1.04e-05	9.15e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP1A1—kidney cancer	9.87e-06	8.67e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—POMC—kidney cancer	7.36e-06	6.47e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PTGS2—kidney cancer	5.87e-06	5.16e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PTEN—kidney cancer	5.12e-06	4.5e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PIK3CA—kidney cancer	3.61e-06	3.17e-05	CbGpPWpGaD
